Robert Rothlein

Title: The Innovations of Robert Rothlein

Introduction

Robert Rothlein is a notable inventor based in Summerfield, NC (US). He has made significant contributions to the field of biotechnology, particularly in the development of RAGE fusion proteins. With a total of 7 patents to his name, Rothlein's work has the potential to impact therapeutic approaches for various pathologies.

Latest Patents

Rothlein's latest patents include innovative discoveries related to RAGE fusion proteins and their applications. One of his patents, titled "RAGE fusion proteins and methods of use," discloses RAGE fusion proteins that comprise RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. These fusion proteins may utilize a RAGE polypeptide domain that includes a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C2 domain. This design allows for specific, high-affinity binding to RAGE ligands, making them promising candidates for therapeutics targeting RAGE-mediated pathologies. Another patent, "Nucleic acid molecules encoding rage fusion proteins," further explores the formulation and therapeutic use of these RAGE fusion proteins.

Career Highlights

Rothlein is currently associated with Transtech Pharma, Inc., where he continues to advance his research and development efforts. His work at Transtech Pharma has positioned him as a key player in the biotechnology sector, focusing on innovative solutions for complex medical challenges.

Collaborations

Rothlein collaborates with esteemed colleagues such as Adnan M M Mjalli and Ye Edward Tian. These partnerships enhance the research environment and foster the development of groundbreaking technologies.

Conclusion

Robert Rothlein's contributions to the field of biotechnology through his patents and collaborations highlight his role as an influential inventor. His work on RAGE fusion proteins showcases the potential for innovative therapeutic solutions in addressing RAGE-mediated pathologies.